Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review

Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of developing progressive fibrosis, cirrhosis, and hepatocellular carcinoma. As of now, there are no FDA-approved treatments for NAFLD/non-alcoholic steatohepatitis (NASH) or its associated fibrosis. Although many drugs a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Nabeel R, Kulkarni, Vaishnavi Vijaya, Pokhrel, Sushil, Akram, Hamna, Abdelgadir, Arowa, Chatterjee, Abanti, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173657/
https://www.ncbi.nlm.nih.gov/pubmed/35693370
http://dx.doi.org/10.7759/cureus.24829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173657/
https://www.ncbi.nlm.nih.gov/pubmed/35693370
http://dx.doi.org/10.7759/cureus.24829

Ejemplares similares